Alaya.bio, a Villejuif, France- and Cambridge, MA-based in vivo gene delivery biotech company, acquired all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.
The amount of the deal was not disclosed.
This acquisition accelerates Alaya.bio’s programs, providing data showing preclinical proof of concept of the anti-tumoral efficacy of in vivo engineered CAR T cells in immunocompetent mouse models. It includes a broad patent portfolio, preclinical data, and exclusive licenses for polymeric nanoparticle technology. In addition, Alaya.bio obtained a fully equipped laboratory space, and state-of-the-art viral vector bioproduction facilities, optimally positioning Alaya.bio for collaborations and accelerated development of its in vivo gene delivery platform.
Founded by Cécile Bauche, CSO, and Renaud Vaillant, CEO, Alaya.bio is a biotechnology company dedicated to advancing in vivo gene delivery platform, particularly in the field of CAR T cell immunotherapy. The proprietary technology relies on a targeting polymeric nanoparticle comprised of a lentiviral vector coated by a biodegradable polymer allowing the targeting and transduction of T-cells. The platform technology is designed to enhance the transduction efficiency of quiescent cells, including T cells, NK cells, and stem cells. It can be used either ex vivo (as part of rapid manufacturing processes) or in vivo (in situ transduction within the patient after systemic administration).
For the past nine months, Alaya.bio was a resident of the recently opened Biolabs Paris, which served as a launching pad of the project.
FinSMEs
23/10/2023